Business Description
AVITA Medical Inc
NAICS : 339112
SIC : 5047
28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355
Description
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centres. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 114.84 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 9.65 | |||||
| Beneish M-Score | 2.82 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 134.5 | |||||
| 3-Year EBITDA Growth Rate | 8.1 | |||||
| 3-Year EPS without NRI Growth Rate | 5.1 | |||||
| 3-Year FCF Growth Rate | 5.8 | |||||
| 3-Year Book Growth Rate | 176.8 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 91.19 | |||||
| 9-Day RSI | 83.86 | |||||
| 14-Day RSI | 77.09 | |||||
| 6-1 Month Momentum % | -34.16 | |||||
| 12-1 Month Momentum % | -66.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.96 | |||||
| Quick Ratio | 13.68 | |||||
| Cash Ratio | 12.83 | |||||
| Days Inventory | 113.52 | |||||
| Days Sales Outstanding | 35.28 | |||||
| Days Payable | 184.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 27 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.96 | |||||
| Operating Margin % | -89.98 | |||||
| Net Margin % | -89.97 | |||||
| ROE % | -25.78 | |||||
| ROA % | -23.78 | |||||
| ROIC % | -196.86 | |||||
| ROC (Joel Greenblatt) % | -964.96 | |||||
| ROCE % | -25.19 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.68 | |||||
| PB Ratio | 1.85 | |||||
| Price-to-Tangible-Book | 2.1 | |||||
| EV-to-EBIT | -3.44 | |||||
| EV-to-EBITDA | -3.53 | |||||
| EV-to-Revenue | 3.09 | |||||
| EV-to-Forward-Revenue | 1.56 | |||||
| EV-to-FCF | -3.56 | |||||
| Price-to-Net-Current-Asset-Value | 2.48 | |||||
| Price-to-Net-Cash | 2.75 | |||||
| Earnings Yield (Greenblatt) % | -29.07 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 43 | ||
| EPS (TTM) (A$) | -0.314 | ||
| Beta | 0.69 | ||
| Volatility % | 36.73 | ||
| 14-Day RSI | 77.09 | ||
| 14-Day ATR (A$) | 0.121705 | ||
| 20-Day SMA (A$) | 1.74125 | ||
| 12-1 Month Momentum % | -66.11 | ||
| 52-Week Range (A$) | 1.28 - 5.7 | ||
| Shares Outstanding (Mil) | 124.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AVITA Medical Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||